Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance
1. ANGO's Q3 2025 adjusted EPS was 3 cents, surpassing a 13-cent loss estimate. 2. Sales reached $72 million, beating expectations and up 9.2% year-over-year. 3. Gross margin rose to 54%, a 290 basis point improvement from last year. 4. Fiscal 2025 sales forecast is $285-$288 million, ahead of prior estimates. 5. Stock surged 10.09% to $10.63 following the earnings report.